{"filings":[{"id":2253516,"accession_number":"0001493152-26-037979","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-08-14T11:35:47+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q2 net loss $7.1M; LP-300 PFS benefit deepens; OMAI spin-off","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net loss $7.1M ($0.57/share) vs $4.3M ($0.40) YoY; operating loss down 25% to $3.5M.","Cash $7.4M at June 30, 2026; raised $4.4M gross from May 14 registered direct offering.","LP-300 HARMONIC: median PFS 8.9 mo in L858R patients completing 6 cycles (n=9) vs 8.4 mo overall (n=16); HR 0.37; FDA cleared protocol amendments to focus on L858R and extend to 8 cycles.","EMA cleared LP-184 Phase 1b/2 bladder cancer trial at Rigshospitalet, Denmark; FDA cleared TNBC trial; USPTO Notice of Allowance for three-gene signature.","Open Medicine AI established as separate company with executed commercial licenses; plans to raise capital at OMAI level."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2026836,"accession_number":"0001493152-26-035864","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-08-03T21:24:41+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantern Pharma spins out AI platform as Open-Medicine AI, signs commercial licenses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lantern Pharma (LTRN) creates Open-Medicine AI as a separate company to commercialize its multi-agent AI co-scientist platform.","Commercial licensing agreements executed between Lantern and OMAI for withZeta.ai-related models, data, and assets.","Board approved; structure consistent with May 2026 registered direct financing led by Empery Asset Management.","OMAI to expand beyond oncology into other disease areas; global AI drug discovery market projected >$10B by 2030.","AI Center of Excellence in Bengaluru, India established in Q1 2026 to support platform scaling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787011,"accession_number":"0001493152-26-026696","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-06-01T23:40:29+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantern Pharma uses presentation to discuss Harmonic Phase 2 trial of LP-300","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1 on June 1, 2026, regarding LP-300 in Harmonic Phase 2 trial.","No specific trial results or financial data disclosed in the 8-K filing itself.","Investors must review the presentation exhibit for detailed clinical updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470757,"accession_number":"0001493152-26-023758","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-05-15T20:07:33+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantern Pharma Q1 net loss down 27% YoY; FDA clears LP-300 trial amendments, IND for pediatric CNS cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.","R&D expenses fell 47% YoY to $1.7M; cash & marketable securities $6.3M at March 31, plus $4.4M May financing.","Successful FDA Type C meeting for LP-300 HARMONIC trial; protocol amended to focus on EGFR exon 21 L858R mutation as single-arm study.","IND cleared for Starlight Therapeutics' STAR-001 pediatric CNS cancer trial (ATRT); Rare Pediatric Disease Designations.","Launched withZeta.ai commercial AI platform; announced plan to spin it into independent entity."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":445197,"accession_number":"0001493152-26-023200","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-05-14T21:26:31+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lantern Pharma raises $4.4M through registered direct offering; plans to spin out AI platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 2,135,923 shares at $2.06/share (or pre-funded warrants) plus unregistered warrants for equal shares.","Unregistered warrants have exercise price $2.27, exercisable after 6 months, expire 5 years from initial exercise.","Up to additional $4.85M gross proceeds if warrants fully exercised; no assurance of exercise.","Company plans to separate AI platform withZeta.ai into independent entity; may become publicly listed.","Suspended ATM sales under July 2025 agreement with ThinkEquity; agreement remains in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95276,"accession_number":"0001493152-26-016047","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantern Pharma demonstrates withZeta.ai AI co-scientist platform; no financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Live demo of withZeta.ai, a multi-agentic AI platform for rare cancer drug discovery and clinical design.","Presentation discussed platform capabilities, commercial architecture, rare cancer market opportunity, and competitive positioning.","Outlined near-term revenue strategy and growth roadmap for the withZeta.ai platform.","Replay of the demonstration available at provided Zoom link; presentation furnished as Exhibit 99.1.","No specific financial or operational metrics were provided in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108213,"accession_number":"0001493152-26-013608","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.","Full-year net loss $17.1M ($1.57/share) vs $20.8M ($1.93/share) in 2024; R&D expenses down 29% to $11.5M.","LP-300 HARMONIC trial: FDA Type C meeting scheduled mid-May 2026 to discuss protocol amendments focusing on EGFR exon 21 L858R patients.","LP-184 Phase 1a complete: 48% clinical benefit rate; Phase 1b/2 trials planned in TNBC, NSCLC with STK11/KEAP1 mutations.","withZeta.ai beta testing with 25+ biotech firms; company denies false report of CEO resignation, confirms Panna Sharma remains CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108212,"accession_number":"0001493152-26-003314","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantern Pharma demonstrates AI tools for rare cancers at Jan 22 event","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Event hosted on Jan 22, 2026 to showcase initial AI tools and multi-agentic system for rare cancers.","Presentation furnished as Exhibit 99.1; no financial results or clinical data disclosed.","Company discusses AI-driven drug development platform, but no specific milestones or partnerships announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124648,"accession_number":"0001493152-25-022134","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q3 net loss $4.2M; LP-184 Phase 1a achieves 48% clinical benefit rate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.2M ($0.39/shr) vs $4.5M loss in Q3 2024; cash $12.4M, runway into Q3 2026.","LP-184 Phase 1a met all endpoints; 48% clinical benefit rate at therapeutic dose; RP2D set at 0.39 mg/kg.","FDA Type C meeting provides regulatory path for pediatric CNS trial in ATRT; spironolactone combo strategy confirmed.","LP-300 HARMONIC trial data presented at Japan Lung Cancer Society; Japan enrollment completed.","RADR AI platform modules commercial-ready; predictBBB 94.1% accuracy, LBx-AI 86% accuracy for treatment response."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141336,"accession_number":"0001493152-25-014652","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lantern Pharma shareholders elect all six directors, approve option repricing, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected: Keyser (2.21M for), Sharma (2.21M), Chandru (2.20M), Maccecchini (2.21M), Schalop (2.21M), Silberstein (2.21M); broker non-votes 5.19M.","One-time repricing of stock options under 2018 Equity Incentive Plan approved: 1.46M for, 759K against, 30K abstain, 5.19M broker non-votes.","Ratification of EisnerAmper LLP as auditor for FY2025 passed: 7.37M for, 44K against, 26K abstain; no broker non-votes on this item."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141335,"accession_number":"0001641172-25-023489","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantern Pharma Q2 net loss narrows to $4.33M; LP-184 Phase 1a complete, complete responses in two trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.","LP-184 Phase 1a enrollment complete (65 patients); MTD and RP2D established; advancing to Phase 1b/2 in TNBC and bladder cancer.","LP-300 HARMONIC trial shows complete response in a 70-year-old NSCLC patient who failed three prior therapies.","LP-284 achieves complete metabolic response in heavily pretreated DLBCL patient after two cycles.","Cash runway extends at least into June 2026; no quarterly earnings call planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141334,"accession_number":"0001641172-25-021407","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Lantern Pharma appoints Lee T. Schalop to Board, reduces shareholder quorum to 33.33%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Lee T. Schalop, M.D., former CEO of Oncoceutics (sold to Chimerix for $450M), to the Board effective July 24, 2025.","Dr. Schalop has extensive biotech and finance background including roles at Morgan Stanley, J.P. Morgan, Credit Suisse.","Board amended By-laws to reduce stockholder quorum requirement from majority to one-third (33.33%) of shares entitled to vote.","Amendment to Section 2.07 effective immediately on July 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141333,"accession_number":"0001641172-25-017810","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lantern Pharma enters $15.53M ATM equity offering agreement with ThinkEquity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM Sales Agreement allows sale of up to $15,530,000 in common stock through ThinkEquity as agent.","Agent commission set at 3.0% of gross proceeds; sales at prevailing market prices on Nasdaq.","Company has no obligation to sell any shares; agreement terminates upon full sale or earlier termination.","Offering registered under existing S-3 shelf (File No. 333-279718); prospectus supplement filed July 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159142,"accession_number":"0001641172-25-010541","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.","Net loss $4.5M ($0.42/share) vs $5.4M ($0.51/share) in Q1 2024; R&D expense $3.3M vs $4.3M.","LP-184 Phase 1a solid tumor trial enrollment expected to finish by end of June 2025; full data readout in Q3 2025.","FDA cleared Phase 1b/2 protocols for LP-184 in TNBC (with olaparib) and STK11/KEAP1-mutant NSCLC.","LP-300 HARMONIC trial additional data including Asian expansion cohort anticipated in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177604,"accession_number":"0001641172-25-000917","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma reports Q4 2024 net loss $5.9M ($0.54/share); cash $24M as pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2024 was $5.9M ($0.54 per share) vs $4.2M ($0.39) in Q4 2023; full year net loss $1.93/share vs $1.47.","Cash, cash equivalents and marketable securities $24.0M as of Dec 31, 2024, down from $41.3M at Dec 31, 2023.","HARMONIC trial lead-in cohort (LP-300) showed 86% clinical benefit rate and 43% ORR in never-smoker NSCLC; expansion cohort reinforcing trends.","LP-184 received two FDA Fast Track Designations (GBM, TNBC) and three Rare Pediatric Disease Designations; Phase 1a on cohort 11.","RADR platform surpassed 100B oncology data points; MD Anderson collaboration shows LP-184 synergy with anti-PD1 in TNBC preclinical models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177603,"accession_number":"0001493152-25-001685","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lantern Pharma amends CSO Bhatia's agreement: term to Jan 2026, reduced hours, $189,600 salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kishor G. Bhatia, CSO, employment term extended to January 15, 2026.","Minimum weekly hours reduced to 24 for scientific, clinical, and therapeutic development.","Annual base salary proportionately adjusted to $189,600 effective first pay period January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194308,"accession_number":"0001493152-24-044124","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q3 2024 earnings call held; no financial details in 8-K","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Conference call and live webinar occurred on November 7, 2024 for Q3 results.","Presentation covering financial and operating results furnished as Exhibit 99.1.","No specific revenue, EPS, or guidance figures were disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194307,"accession_number":"0001493152-24-044006","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.","LP-300 Harmonic trial: 86% clinical benefit rate, 43% objective response in 7-patient lead-in; expanded to Japan and Taiwan.","LP-184 Phase 1a: 9 cohorts dosed, no DLTs; FDA Fast Track for GBM; Phase 1b/2a expected early 2025.","LP-284 Phase 1a: fourth cohort dosing, no DLTs; additional hematology sites planned; potential Phase 1b/2 by mid-2025.","R&D expenses $3.7M (up from $2.2M); G&A $1.5M ($1.3M); 10.8M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210646,"accession_number":"0001493152-24-030764","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.","LP-300 Harmonic Phase 2 lead-in (7 pts): 86% clinical benefit rate, 43% objective response rate, no dose-limiting toxicities.","LP-184 Phase 1A: 7 cohorts dosed, no DLTs; LP-284 third cohort dosing, no DLTs; both on track.","RADR platform collaboration with Oregon Therapeutics for XCE853; Starlight Therapeutics advancing STAR-001 for recurrent GBM.","Japanese patent issued for LP-284; Webinar Wednesdays launched for AI and oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229010,"accession_number":"0001493152-24-024110","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five directors elected: Keyser, Sharma, Chandru, Maccecchini, Silberstein; each received ~3.04M votes for, ~22K withheld.","Amendment to 2018 Equity Incentive Plan approved to increase share pool by 125,000 shares; 2.89M for, 128K against.","Ratification of EisnerAmper LLP as independent auditor for FY2024 passed with 7.17M votes for, 40K against.","Broker non-votes of 4.23M on director election and equity plan; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229009,"accession_number":"0001493152-24-021353","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Lantern Pharma amends bylaws to streamline director count setting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board of Directors approved amendment to Section 3.02 of Bylaws on May 23, 2024, effective immediately.","Previous language required a majority of total directors (including vacancies) to set board size; now any board resolution suffices.","Authorized board size remains unchanged at minimum 3 and maximum 9 directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229008,"accession_number":"0001493152-24-018426","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q1 2024 net loss $5.4M, cash $38.4M; clinical trials advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.4M ($0.51/share) vs $3.9M ($0.36/share) in Q1 2023; R&D expense $4.3M vs $2.6M.","Cash, cash equivalents & marketable securities $38.4M at Mar 31, 2024, down from $41.3M at Dec 31, 2023.","Phase 1 trials for LP-184 and LP-284 continue with no dose-limiting toxicities; LP-184 enrollment to complete summer 2024.","Regulatory allowance granted to begin Phase 2 Harmonic trial in Japan and Taiwan for LP-300 in never-smoker NSCLC.","ADC program advanced: novel cryptophycin-based ADC shows picomolar potency and 80% cancer cell kill rate in preclinical studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247618,"accession_number":"0001493152-24-010303","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.","Cash, equivalents and marketable securities $41.3M at Dec 31, 2023, down from $55.2M a year earlier.","LP-184 Phase 1A continuing; initial readout expected late summer/early fall 2024. LP-284 Phase 1 dosed first patients.","Starlight Therapeutics hired CMO; plans Phase 1B/2 CNS trial in H2 2024. RADR platform surpassed 60B datapoints.","Share repurchase of 145,348 shares at $3.44/sh in November 2023 reduced outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265080,"accession_number":"0001493152-23-046572","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lantern Pharma raises CSO and CFO salaries and bonus targets effective Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CSO Kishor Bhatia base salary increased to $316,000; target bonus set at 40% of base.","CFO David Margrave base salary increased to $413,800; target bonus set at 40% of base.","Changes effective January 1, 2024, based on independent compensation advisory firm analysis.","Amendments to employment agreements approved by Compensation Committee and Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265079,"accession_number":"0001493152-23-042670","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2023-11-24T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Lantern Pharma to repurchase 145K shares from Bios Entities at $3.44/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company agreed to buy 145,348 common shares from Bios Fund I entities at $3.44/share, total ~$500K.","Bios Entities own ~14.7% of outstanding shares; sale for their own working capital and liquidity.","Transaction expected to close by November 30, 2023; customary reps, warranties, and covenants.","Buyback represents about 0.5% of shares outstanding (based on recent filings)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265078,"accession_number":"0001493152-23-039900","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q3 net loss $3.2M ($0.29/shr); cash $44.9M; LP-284 IND cleared, LP-184 dosed first patient","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M ($0.29/shr) vs $2.3M ($0.21/shr) in Q3 2022; R&D rose to $2.2M from $0.7M due to prior-year one-time payment.","Cash, equivalents, and marketable securities $44.9M at Sep 30 vs $55.2M at Dec 31; runway into at least Q3 2025.","Received FDA IND clearance for LP-284 Phase 1 trial in refractory non-Hodgkin's lymphomas; dosed first patient in LP-184 Phase 1 solid tumor basket trial.","RADR AI platform surpassed 36B oncology datapoints; new modules for ADC design, BBB permeability prediction, and IO combination therapy.","Phase 2 Harmonic trial of LP-300 in never-smoker NSCLC expanded to additional U.S. sites and Asia; Dr. Joseph Treat named lead PI."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265077,"accession_number":"0001493152-23-037907","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lantern Pharma announces unexpected death of director Dr. Franklyn Prendergast","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Franklyn Prendergast died unexpectedly; company learned on October 17, 2023.","Prendergast had served as a director of Lantern Pharma since October 2019.","No replacement or board succession plan disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282280,"accession_number":"0001493152-23-027346","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q2 2023 net loss $4.7M; cash $48.0M; LP-184 IND cleared, LP-284 IND imminent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $48.0M at June 30, 2023 ($55.2M at Dec 2022); cash runway into 2025.","Net loss $4.7M ($0.44/shr) vs $4.5M ($0.41/shr) in Q2 2022; R&D expenses up to $3.6M from $3.0M.","FDA cleared IND for LP-184; Phase 1 basket trial activated for solid tumors and brain cancers.","LP-284 IND submission expected August 2023; Phase 1 trial targeted for Q4 in non-Hodgkin's lymphomas.","Dosed first patients in Phase 2 Harmonic trial for never-smoker NSCLC; RADR collaboration with Bielefeld University for ADCs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301430,"accession_number":"0001493152-23-022001","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lantern Pharma shareholders elect directors, approve 250K share increase, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, David S. Silberstein.","Amendment to 2018 Equity Incentive Plan approved to increase shares available by 250,000; votes: 4,145,520 For, 96,840 Against, 14,138 Abstain.","Ratification of EisnerAmper LLP as independent auditor for FY 2023 approved with 7,015,460 For, 41,115 Against, 5,164 Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301429,"accession_number":"0001493152-23-015941","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q1 net loss $3.9M; cash $51.5M; first patient dosed in Phase 2 Harmonic trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities $51.5M as of March 31, 2023; cash runway into 2025.","Net loss $3.9M ($0.36/share) for Q1 2023 vs $4.1M ($0.38/share) for Q1 2022.","Dosed first patient in Phase 2 Harmonic trial for never-smoker NSCLC; multiple additional sites expected by mid-2023.","IND submission for LP-184 anticipated this week; Phase 1A basket trial targeted for mid-2023 in solid tumors and CNS cancers.","Formed subsidiary Starlight Therapeutics to develop LP-184 (STAR-001) for CNS and brain cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321247,"accession_number":"0001493152-23-008242","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma reports FY2022 net loss $14.3M; cash $55.2M; IND timeline for LP-184/LP-284 in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 net loss $14.3M ($1.31/sh) vs $12.4M ($1.13/sh) in FY2021; cash and equivalents $55.2M (Dec 31, 2022) down from $70.7M.","IND submission for LP-184 expected April 2023; LP-284 IND and first-in-human Phase 1 trials targeted for mid-2023.","Phase 2 Harmonic trial (LP-300) activated 5 sites across 12 US locations; first patient dosing anticipated Q2 2023.","Formed wholly-owned subsidiary Starlight Therapeutics for CNS cancers; STAR-001 clinical trials planned for late 2023/early 2024.","RADR platform surpassed 25 billion oncology datapoints; target of 50 billion in coming year; cash runway into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321246,"accession_number":"0001493152-23-001789","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2023-01-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lantern Pharma raises CSO Kishor Bhatia's base salary to $235,000 effective Jan 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to employment agreement increasing annual base salary to $235,000.","Increase takes effect with the first pay period in January 2023.","Dr. Bhatia continues as Chief Scientific Officer of Lantern Pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339353,"accession_number":"0001493152-22-030817","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q3 2022 net loss improves to $2.3M; cash $57.8M, pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.3M ($0.21/shr) vs $4.1M ($0.36/shr) in Q3 2021; R&D expenses fell to $0.7M.","Cash, equivalents and marketable securities $57.8M as of Sep 30, 2022; cash runway into 2025.","Harmonic Phase 2 trial (LP-300) activated first two US sites; new U.S. patent issued for LP-300 through 2032.","IND-enabling studies for LP-184 and LP-284 expected complete Q1 2023; Phase 1 launches targeted H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356721,"accession_number":"0001493152-22-021614","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q2 net loss $4.5M; launches Phase 2 Harmonic trial for LP-300 in never-smoker NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.5M ($0.41 per share) vs $2.3M ($0.21) in Q2 2021; R&D spend increased to $3.0M from $1.2M.","Cash, cash equivalents, and marketable securities $62.2M as of June 30, 2022, down from $79.6M a year ago; cash runway into 2025.","Phase 2 Harmonic trial for LP-300 launched; enrollment begins Q3 2022; initial results expected Q4 2023.","INDs for LP-184 and LP-284 planned for early 2023; Phase 1 trials for LP-184 (CNS + solid tumors) and LP-284 (NHL) anticipated in H1 2023.","RADR platform now exceeds 21 billion data points; Dr. Maria Maccecchini elected to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375182,"accession_number":"0001213900-22-032619","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lantern Pharma shareholders elect six directors and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected: Keyser, Sharma, Chandru, Maccecchini, Prendergast, Silberstein.","EisnerAmper LLP ratified as independent auditor for FY 2022 with 7.48M shares for, 18,585 against.","Director votes ranged from 3.85M to 3.85M for; broker non-votes of 3.67M on each director election.","No broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375181,"accession_number":"0001213900-22-023584","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q1 net loss $4.1M; cash $65.2M, RADR platform tops 20B data points","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $65.2M at March 31, 2022 vs $70.7M at Dec 31, 2021; net cash used $5.3M in Q1.","Net loss $4.1M ($0.38/share) vs $2.5M ($0.24) in Q1 2021; R&D expenses rose to $2.7M from $1.3M.","RADR AI platform surpassed 20 billion data points; on track for 25 billion by year-end 2022.","IND for LP-184 targeted for Q3 2022; HARMONIC Phase 2 trial for LP-300 expected to start enrollment summer 2022.","Share repurchase program extended; $3.6M remaining authorized through July 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375180,"accession_number":"0001213900-22-021526","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma board nominee Maria Maccecchini; director Leslie Kreis not standing for reelection","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leslie W. Kreis, Jr. will not stand for reelection at the June 8, 2022 annual meeting.","Maria L. Maccecchini, Ph.D., CEO of Annovis Bio (ANVS), nominated to the board.","She brings over 30 years biopharma experience in neurodegenerative disease and drug development.","Kreis served since 2019; CEO Panna Sharma thanked him for guiding Lantern through IPO and growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375179,"accession_number":"0001213900-22-021397","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lantern Pharma provides disclosure channels reminder; no material news","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing details company's website, press releases, SEC filings, newsletters, and social media as information channels.","No financial results, clinical updates, or material events reported.","Company reiterates emerging growth company status and extended transition period election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393561,"accession_number":"0001213900-22-013992","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lantern Pharma extends share repurchase program to July 31, 2022; $3.6M remaining authorization.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board extended existing share repurchase program through July 31, 2022, with $7M total authorization.","Since Nov 2021, 475,157 shares repurchased for ~$3.4M; $3.6M remaining as of March 21, 2022.","Company had $70.7M cash, equivalents, and marketable securities as of Dec 31, 2021.","Repurchases may occur on open market or privately; program may be suspended at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393560,"accession_number":"0001213900-22-011579","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma reports FY2021 net loss $12.4M; cash $70.7M; RADR platform surpasses 18B data points","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $70.7M at Dec 31, 2021, up from $19.2M at year-end 2020; share repurchase authorized up to $7M.","FY2021 net loss $12.4M ($1.13/share) vs $5.9M ($1.37/share) in FY2020; R&D expense rose to $7.6M.","RADR AI platform grew from 1.2B to over 18B data points during 2021; target of 25B by end 2022.","LP-300 Phase 2 Harmonic trial for never-smoker NSCLC expected to launch in 2022; LP-184 multiple Phase 1 trials in 2022.","LP-184 received Orphan Drug Designations for pancreatic cancer, GBM, ATRT; Rare Pediatric Disease Designation for ATRT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393559,"accession_number":"0001213900-22-003180","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2022-01-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lantern Pharma receives Rare Pediatric Disease and Orphan Drug designations for LP-184 in ATRT","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 to treat atypical teratoid rhabdoid tumor (ATRT).","LP-184 is the third Lantern program to receive Orphan Drug Designation; prior designations for pancreatic cancer and malignant glioma.","Rare Pediatric Disease Designation may qualify Lantern for a Priority Review Voucher upon FDA approval of LP-184.","ATRT is an aggressive CNS tumor; nearly 90% of pediatric cases involve SMARCB1 mutations, which LP-184 targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412089,"accession_number":"0001213900-21-061032","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2021-11-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lantern Pharma announces $7M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $7M of common stock repurchases.","Cash and equivalents totaled $73.8M as of Sept 30, 2021.","Approximately 11.2M shares outstanding as of Oct 29, 2021.","CEO states program reflects confidence in pipeline and platform.","Repurchases may occur on open market or privately; program can be modified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412088,"accession_number":"0001213900-21-055781","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2021-11-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q3 net loss $4.05M, cash $73.8M; RADR hits 10B datapoints, LP-184 ODD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.05M ($0.36 per share) vs $1.70M in Q3 2020; R&D expenses $2.96M up from $0.60M.","Cash and marketable securities $73.8M as of Sep 30, 2021, up from $19.2M at Dec 31, 2020.","RADR platform surpassed 10 billion curated oncology data points, up from 4.6B in earlier 2021.","LP-184 received Orphan Drug Designation from FDA for pancreatic cancer and glioblastoma.","Announced strategic collaborations with Deep Lens and Code Ocean; planning Phase 2 trial for LP-300."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430803,"accession_number":"0001213900-21-039285","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma reports Q2 2021 net loss $2.3M; cash $79.6M; positive LP-184 pancreatic data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.3M ($0.21/sh) vs $833K ($0.31/sh) in Q2 2020; R&D expenses rose to $1.16M.","Cash, equivalents, and marketable securities $79.6M at June 30, up from $19.2M Dec 31, 2020.","Preclinical data for LP-184 showed 93% avg tumor volume reduction in pancreatic cancer models.","Preparing LP-300 Phase 2 trial site selection and GMP batch for NSCLC in Q3 2021.","Reacquired LP-100 (Irofulven) rights from Allarity; $1M upfront plus up to $16M milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}